Approximately 1.6 million Americans suffer from inflammatory bowel diseases (IBD); Ulcerative colitis (UC) and Crohn’s disease (CD). The goal of IBD therapy is to induce deep remission characterized by resolution of both endoscopic and histologic abnormality. However, frequent endoscopy is not always feasible for disease monitoring, leaving physicians to rely on less invasive markers of disease activity. Currently available biomarkers C-Reactive Protein (CRP) and Fecal Calprotectin (FC) have demonstrated utility as markers of disease activity, but each test has limitations for diagnostic use in IBD.